> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Complete Response Letter on Evolus Botox Competitor
- URL: https://www.fdaweb.com/complete-response-letter-on-evolus-botox-competitor/
- Published: 2018-05-16T12:00:00.000Z
- Updated: 2026-09-15T00:05:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141453

FDA has issued Evolus a complete response letter related to its BLA for DWP-450 (prabotulinumtoxinA) for treating glabellar lines, also known as frown lines, in adult patients. If approved, DWP-450 would be a competitor to Allergan’s Botox.

The FDA letter reportedly cited chemistry, manufacturing, and controls-related deficiencies. “No deficiencies were related to clinical or non-clinical matters,” the company says. Evolus expects to respond with a complete submission to FDA within 90 days. 

Additionally, the company says it was recently provided with an Establishment Inspection Report related to contract-manufacturer Daewoong Pharmaceutical Co. “confirming the favorable completion of its pre-approval inspection of Daewoong’s manufacturing facility in South Korea...The DWP-450 manufacturing facility is fully validated by Daewoong under current good manufacturing practice requirements, and has capacity expected to meet anticipated product demand.”